Hematology

Hematology is the area of medicine dealing with diseases of the blood.

At Sobi North America, we’re advancing blood cancer treatments that have life-changing potential.

We are committed to delivering treatment options for patients with Immune thrombocytopenia (ITP), a rare autoimmune disease affecting platelet production and characterized by fatigue, bruising and bleeding. Only nine or ten people in every 100,000 have ITP. Until recently, treatment options are ruled by compromise. Today, there is increased awareness of the available treatment options, and better life may be possible for people living with ITP.

Thrombocytopenia is a deficiency of thrombocytes, or platelets. Platelets are tiny, colorless cell fragments in the blood that form clots, which stop or prevent bleeding.

Thrombocytopenia that is not caused by a previous disease is known as primary ITP. If the disease is caused by another condition affecting the immune system (such as HIV), it is referred to as secondary.

Our portfolio also addresses cytopenic myelofibrosis, a rare blood disease characterized by scarring of the bone marrow, as well as disruption of the normal production of blood cells. Approximately 20,000 patients in the US are diagnosed with myelofibrosis, and about one-third of those have severe thrombocytopenia, with a median overall survival of 15 months.

We are dedicated to delivering the promise of a better life for those living with rare and severe blood diseases.

Sobi’s focus in North America within hematology